{
    "title": "103_hr1926",
    "content": "The \"National Narcotics Leadership Act Amendments of 1993\" allows the Director to request funding for specific initiatives in line with the President's priorities for the National Drug Control Strategy. Additionally, there are amendments regarding the implementation of the National Drug Control Strategy and a report on reprogramming and office personnel restrictions. The Director must report quarterly to Congress on the need for reprogramming funds over $5,000,000 for National Drug Control Program activities. Additionally, federal officers in the Office of National Drug Control Policy appointed by the President cannot participate in federal election campaign activities, but can make contributions to individual candidates. The National Drug Control Strategy Outcome Measures are outlined in Section 4. Section 1005(a) of the National Narcotics Leadership Act of 1988 is amended to include an evaluation of Federal drug control effectiveness in the National Drug Control Strategy. This evaluation will assess the reduction of drug use through various surveys and studies, including high-risk populations. The evaluation of Federal drug control effectiveness in the National Drug Control Strategy includes studies on high-risk populations such as school dropouts, the homeless, arrestees, parolees, and juvenile delinquents. It also assesses the reduction of drug availability by measuring quantities of cocaine, heroin, and marijuana available in the United States, as well as the cultivation and destruction of poppy and coca hectares. The evaluation of Federal drug control effectiveness in the National Drug Control Strategy includes assessing the number of hectares of poppy and coca cultivated and destroyed, metric tons of heroin and cocaine seized, cocaine processing labs destroyed, changes in price and purity of heroin and cocaine, controlled substances diverted from legitimate sources, and the effectiveness of Federal technology programs in improving drug detection capabilities at U.S. ports of entry. The assessment of drug-related consequences in the United States includes estimating burdens on hospital emergency rooms, national healthcare costs, drug-related crime, and the contribution of drugs to public health issues like HIV and other communicable diseases. The assessment of drug treatment in the United States includes evaluating public and private treatment capacity, availability of treatment on demand, and data on intravenous drug users and pregnant women. The assessment includes evaluating treatment availability for intravenous drug users and pregnant women, estimating the number of beneficiaries, and assessing the success of drug treatment programs at federal and state levels. The Director evaluates drug use measurement instruments, coverage adequacy, and corrective actions in the National Drug Control Strategy. The Director evaluates drug use measurement instruments, coverage adequacy, corrective actions, and proposes remedies to make treatment available to individuals seeking it. Federal agencies cooperate with the Director to provide drug-related information for the National Drug Control Strategy. The Director evaluates drug use and availability in the US, reporting to the President and Congress on the effectiveness of various programs under the National Drug Control Strategy. The Director of the Office of National Drug Control Policy is added as a member of the National Security Council. Additionally, a Counter-Drug Technology Assessment Center is established. The National Narcotics Leadership Act of 1988 is amended to include identifying and supporting the application of technology in drug treatment. Additionally, the Office of National Drug Control Policy receives assistance and support from the Advanced Research Project Agency. The National Narcotics Leadership Act of 1988 is amended to provide assistance and support to the Office of National Drug Control Policy by the Director of the Advanced Research Project Agency. Section 1008 is repealed and redesignated to follow section 1007. SEC. 7. The Director may pay for necessary expenses for consultation on the National Drug Control Strategy. SEC. 8. Authorization of appropriations for fiscal year 1994. SEC. 9. The Office of National Drug Control Policy terminates on September 30, 1994. The House of Representatives passed the document on November 21, 1993. Attest: DONNALD K. ANDERSON, Clerk."
}